Cell therapy for severe autism-related self-injury and aggression
Part of Mental health clinical trials.
This trial tests a new cell-based treatment (called VGN-Ex05e) for young people with autism who have severe self-injury or aggression that hasn't improved with standard treatments. The treatment is given as a one-time injection into a specific area of the brain (nucleus accumbens) to help calm these behaviors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age: Between 7 and 18 years old.
- Diagnosed with autism, confirmed by a standard test (called ADOS-2).
- Must have had self-injury or aggression in the last 3 months that is strong enough to meet the study's severity level.
- Must have already tried at least two types of medication (one antipsychotic, one mood stabilizer) without enough help or with bad side effects.
- Must be able to undergo an MRI and be free of certain medical conditions (like poorly controlled epilepsy or active infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether deep brain stimulation, a surgical treatment that uses implanted electrodes to regulate brain activity, can reduce severe and persistent aggression in adults who have not improved with other treatments. It may offer a new option for people with schizophrenia or autism who experience aggressive behavior that is hard to control.
This study tests whether deep brain stimulation can reduce severe self-injurious behaviors in children with autism. If standard treatments haven't worked, this approach may offer a new option.
This trial tests a new therapy that aims to help the brain grow new connections in children with autism. It uses a non-invasive device, so no surgery or drugs are involved, and it may help improve communication and daily skills.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
This study tests an experimental medication called TB006 for adults with autism. It aims to see if it can help reduce symptoms. Participants must be 18–35, have moderate-to-severe autism, and have a caregiver who can join them.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
Hear when a new Autism spectrum disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.